| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $112.5M | +125.3% |
| SG&A Expense | $30.1M | +141.4% |
| Operating Income | -$142.6M | -128.5% |
| Income Tax | $0 | — |
| Net Income | -$127.5M | -111.2% |
| EPS (Basic) | -$3.33 | +96.3% |
| EPS (Diluted) | -$3.33 | +96.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $96.6M | +178.9% |
| Short-term Investments | $189.4M | +727.0% |
| Current Assets | $290.6M | +379.0% |
| Total Assets | $304.6M | +305.1% |
| Current Liabilities | $33.8M | +70.0% |
| Total Liabilities | $38.1M | +46.3% |
| Stockholders' Equity | $266.6M | +302.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$114.3M | -118.0% |
| Capital Expenditures | $2.2M | +255.1% |
| Investing Cash Flow | -$160.9M | -1731.6% |
| Financing Cash Flow | $337.1M | +480.0% |
| Free Cash Flow | -$116.5M | -119.6% |